Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Opioid-Induced Constipation Market by Type (Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Others), By Application (Hospital, Pharmacy) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Opioid-Induced Constipation Market by Type (Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Others), By Application (Hospital, Pharmacy) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 171295 3300 Pharma & Healthcare 377 243 Pages 4.9 (43)
                                          

The global opioid-induced constipation market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of chronic pain and opioid use disorder, growing number of surgeries and rising geriatric population. Methylnaltrexone Bromide dominated the global opioid-induced constipation market in 2018 with a share of over 50%. It is followed by Lubiprostone with a share of around 30%. Methylnaltrexone Bromide has been used for the treatment of chronic constipation in patients who are taking opioids for more than 3 months. Lubiprostone has been used for the treatment of chronic idiopathic constipation in adults who have not responded to laxatives or fiber therapy. Naloxegol has been approved by FDA for the treatment of opioid induced constipation (OIC) in adults with chronic non-cancer pain receiving long term opioid therapy, who have not responded adequately to laxatives or fiber therapy and when OIC symptoms result in significant discomfort or distress that cannot be managed otherwise. Opioid-induced constipation is a common side effect of opioid use. Opioids are a class of drugs that are used to relieve pain. They work by binding to receptors in the brain and spinal cord, which blocks the transmission of pain signals. Opioids can also slow down bowel movements, which can lead to constipation.

Industry Growth Insights published a new data on “Opioid-Induced Constipation Market”. The research report is titled “Opioid-Induced Constipation Market research by Types (Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Others), By Applications (Hospital, Pharmacy), By Players/Companies Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Opioid-Induced Constipation Market Research Report

By Type

Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Others

By Application

Hospital, Pharmacy

By Companies

Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

243

Number of Tables & Figures

171

Customization Available

Yes, the report can be customized as per your need.


Global Opioid-Induced Constipation Industry Outlook


Global Opioid-Induced Constipation Market Report Segments:

The global Opioid-Induced Constipation market is segmented on the basis of:

Types

Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Pharmacy

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Takeda Pharmaceuticals
  2. Bayer
  3. Sanofi
  4. Mallinckrodt
  5. Salix (Bausch Health)
  6. AstraZeneca
  7. Progenics Pharmaceuticals
  8. Purdue Pharm
  9. Nektar Therapeutics
  10. Daiichi Sankyo
  11. Prestige
  12. GSK
  13. Shionogi

Global Opioid-Induced Constipation Market Overview


Highlights of The Opioid-Induced Constipation Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Methylnaltrexone Bromide
    2. Lubiprostone
    3. Naloxegol
    4. Others
  1. By Application:

    1. Hospital
    2. Pharmacy
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Opioid-Induced Constipation Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Opioid-Induced Constipation Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Opioid-induced constipation (OIC) is a condition that can develop after taking opioids for pain relief. Opioids can cause the bowel to become less responsive, which may lead to difficulty with bowel movements.

Some of the major companies in the opioid-induced constipation market are Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi.

The opioid-induced constipation market is expected to grow at a compound annual growth rate of 5.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Opioid-Induced Constipation Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Opioid-Induced Constipation Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Opioid-Induced Constipation Market - Supply Chain
   4.5. Global Opioid-Induced Constipation Market Forecast
      4.5.1. Opioid-Induced Constipation Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Opioid-Induced Constipation Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Opioid-Induced Constipation Market Absolute $ Opportunity

5. Global Opioid-Induced Constipation Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Opioid-Induced Constipation Market Size and Volume Forecast by Type
      5.3.1. Methylnaltrexone Bromide
      5.3.2. Lubiprostone
      5.3.3. Naloxegol
      5.3.4. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Opioid-Induced Constipation Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Opioid-Induced Constipation Market Size and Volume Forecast by Application
      6.3.1. Hospital
      6.3.2. Pharmacy
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Opioid-Induced Constipation Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Opioid-Induced Constipation Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Opioid-Induced Constipation Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Opioid-Induced Constipation Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Opioid-Induced Constipation Demand Share Forecast, 2019-2026

9. North America Opioid-Induced Constipation Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Opioid-Induced Constipation Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Opioid-Induced Constipation Market Size and Volume Forecast by Application
      9.4.1. Hospital
      9.4.2. Pharmacy
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Opioid-Induced Constipation Market Size and Volume Forecast by Type
      9.7.1. Methylnaltrexone Bromide
      9.7.2. Lubiprostone
      9.7.3. Naloxegol
      9.7.4. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Opioid-Induced Constipation Demand Share Forecast, 2019-2026

10. Latin America Opioid-Induced Constipation Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Opioid-Induced Constipation Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Opioid-Induced Constipation Market Size and Volume Forecast by Application
      10.4.1. Hospital
      10.4.2. Pharmacy
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Opioid-Induced Constipation Market Size and Volume Forecast by Type
      10.7.1. Methylnaltrexone Bromide
      10.7.2. Lubiprostone
      10.7.3. Naloxegol
      10.7.4. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Opioid-Induced Constipation Demand Share Forecast, 2019-2026

11. Europe Opioid-Induced Constipation Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Opioid-Induced Constipation Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Opioid-Induced Constipation Market Size and Volume Forecast by Application
      11.4.1. Hospital
      11.4.2. Pharmacy
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Opioid-Induced Constipation Market Size and Volume Forecast by Type
      11.7.1. Methylnaltrexone Bromide
      11.7.2. Lubiprostone
      11.7.3. Naloxegol
      11.7.4. Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Opioid-Induced Constipation Demand Share, 2019-2026

12. Asia Pacific Opioid-Induced Constipation Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Opioid-Induced Constipation Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Opioid-Induced Constipation Market Size and Volume Forecast by Application
      12.4.1. Hospital
      12.4.2. Pharmacy
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Opioid-Induced Constipation Market Size and Volume Forecast by Type
      12.7.1. Methylnaltrexone Bromide
      12.7.2. Lubiprostone
      12.7.3. Naloxegol
      12.7.4. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Opioid-Induced Constipation Demand Share, 2019-2026

13. Middle East & Africa Opioid-Induced Constipation Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Opioid-Induced Constipation Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Opioid-Induced Constipation Market Size and Volume Forecast by Application
      13.4.1. Hospital
      13.4.2. Pharmacy
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Opioid-Induced Constipation Market Size and Volume Forecast by Type
      13.7.1. Methylnaltrexone Bromide
      13.7.2. Lubiprostone
      13.7.3. Naloxegol
      13.7.4. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Opioid-Induced Constipation Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Opioid-Induced Constipation Market: Market Share Analysis
   14.2. Opioid-Induced Constipation Distributors and Customers
   14.3. Opioid-Induced Constipation Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Takeda Pharmaceuticals
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Bayer
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Sanofi
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Mallinckrodt
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Salix (Bausch Health)
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. AstraZeneca
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Progenics Pharmaceuticals
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Purdue Pharm
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Nektar Therapeutics
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Daiichi Sankyo
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Prestige
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. GSK
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Shionogi
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us